Loading...
Surgical Oncology Billing Services
Qualigenix codes and bills cancer surgery for surgical oncologists, breast and HPB surgeons, and cancer centers. Our CPC- and CCS-certified coders code the neoplasm to the site and laterality the pathology supports, code every return to the OR for the reason it happened, and set up clinical trial claims so routine care is billed correctly.
What It Takes to Bill Cancer Surgery Correctly
Billing cancer surgery correctly means coding the neoplasm precisely, choosing modifier 58, 78 or 79 for every return to the OR inside a global period, splitting payment correctly when two surgeons operate, and marking clinical trial claims with Q0, Q1, Z00.6 and the trial number. Qualigenix does this for surgical oncology programs in 48 states with 98.9% coding accuracy and a 98.2% first-pass clean claim rate on first submission. Call 786-259-0231 to review your cancer surgery denials with a specialist.
01
Neoplasm Coding Precision
ICD-10-CM neoplasm codes depend on details the surgeon and pathologist record: the exact primary site and subsite, laterality, whether the tumor is primary or secondary, and whether the cancer is current or a personal history. A breast cancer coded to "unspecified site" or a metastasis coded as the primary weakens medical necessity for the surgery and every service after it. Once a cancer has been excised and no treatment is directed at it, the history code (Z85.x) applies, which changes how follow-up surgery is justified.
02
Resection and HIPEC Pre-Approval
Most commercial plans require authorization for major oncologic resections, and many require it separately for reconstruction and for cytoreduction with HIPEC. Authorizations often name specific CPT codes, so a case that expands in the OR, such as a planned partial hepatectomy that becomes a trisegmentectomy, needs a retro-authorization or update before the claim goes out.
03
Staged and Return-to-OR Cases
Pathology regularly sends cancer patients back to the OR during the 90-day global of the first surgery. The modifier depends on why. A planned or staged procedure, or one more extensive than the original, such as a re-excision after positive margins, generally takes modifier 58 and starts a new global. An unplanned return for a related complication takes modifier 78, which Medicare pays at the intraoperative portion only, with no new global. An unrelated procedure takes 79. The wrong modifier either loses payment or overpays, and the operative note has to say why the patient went back.
04
Clinical Trial Billing
Under Medicare's clinical trial policy (NCD 310.1), Medicare pays for routine costs in qualifying trials, while items the sponsor pays for must not be billed. On Part B claims, investigational items and services take modifier Q0, routine services take Q1, Z00.6 is reported as a diagnosis, and the eight-digit NCT number goes in item 19 of the CMS-1500 (or REF P4 on the 837P), according to Noridian's clinical trials guidance. A trial claim missing these markers, or one that bills a sponsor-paid service, is a compliance problem as well as a payment one.
05
Out-of-Network Cancer Care
Patients often travel to a cancer center outside their plan's network for a complex resection. Without a single-case agreement or network exception in place before surgery, the claim pays at out-of-network rates or not at all, and the patient receives a large balance bill.
06
Op Note and Pathology Details
The operative note and pathology report together support the codes: the extent of resection, the number and location of nodes removed, frozen-section results, margin status, and intraoperative findings that changed the plan. These details justify add-on codes, modifier 22 for unusual work, and the choice between 58 and 78 on a return trip.
How Qualigenix Protects Cancer Surgery Revenue
Each gap above maps to a step in how Qualigenix codes, authorizes and bills cancer surgery.
Neoplasm and Procedure Coding
Certified coders (CPC and CCS) code each case from the operative note and the final pathology, assigning primary site, laterality, metastases and history codes the pathology supports, and querying the surgeon when the report and note disagree. Across all Qualigenix clients, coding accuracy is 98.9%.
Resection and HIPEC Authorizations
We submit authorizations for resections, reconstruction and HIPEC with staging and imaging attached, and we update or retro-authorize when the procedure performed differs from the one approved.
Global-Period Tracking
We track every open global period by patient and surgeon, and code each return to the OR with 58, 78 or 79 based on the documented reason. Margin re-excisions are matched to the original procedure and the pathology report.
Clinical Trial Claim Setup
For trial patients, we read the coverage analysis, mark routine services with Q1 and investigational items with Q0, add Z00.6 and the NCT number, and keep sponsor-paid items off the claim.
Network and Benefit Checks
Before surgery, we confirm the surgeon and facility are in network for the patient's plan, and request a single-case agreement or network exception when they aren't.
Pre-Bill Op Note Review
A coder compares the op note and pathology with the codes and modifiers before release, and queries the surgeon on missing node counts, margin status or the reason for a return to the OR.
Bundling and Co-Surgery Appeals
We correct and appeal bundling, co-surgery and global-period denials with the op note and pathology attached, and coordinate modifier 62 across both surgeons' claims. Across all specialties, 79% of the denials Qualigenix works are overturned.
Cancer Program Compliance
Compliance monitoring for cancer programs covers sampled reviews of teaching-physician documentation, co-surgery claims and clinical trial claims. Qualigenix holds a 98.6% compliance and audit pass rate.
CASE STUDY 01
How a 3-provider podiatry group cleared $214K in aged A/R
THE SITUATION
A 3-provider podiatry group with roughly 60% Medicare payer mix carried $412,000 in A/R, 38% of it past 120 days. Routine foot care claims (11720, 11721, 11055–11057) had stalled on inconsistent Q7/Q8/Q9 modifiers and class-finding documentation, so payers held or partially paid and nobody worked the remainder. Medicare crossover to secondaries was not being posted, and small patient balances were written off.
WHAT QUALIGENIX DID
We ran a full A/R aging segmentation, worked claims by payer and denial reason rather than by date, rebilled the stalled routine-care claims with corrected modifiers, and reactivated secondary and crossover billing.
Key Outcomes & Turnaround
38% to 14%A/R past 120 days
$214,000recovered from aged A/R
90 daysto turn it around
~60%Medicare payer mix
Audited Practice Results
How a solo podiatrist lifted first-pass acceptance to 96%
THE SITUATION
A solo podiatrist coding 320 encounters a month was stuck at 82% first-pass acceptance. Routine foot care went out without the systemic-condition diagnosis pairing and class findings Medicare requires, so it read as non-covered. Wound debridement was coded to the wrong depth (11042 for skin and subcutaneous where the note supported 11043 for muscle and fascia). Same-day E/M with a procedure went out without modifier 25 and got bundled.
WHAT QUALIGENIX DID
We rebuilt the coding workflow: diagnosis-to-CPT pairing rules for at-risk foot care, correct Q-modifier logic, depth-based debridement coding tied to the operative note, and disciplined use of modifiers 25 and 59/XS.
Key Outcomes & Turnaround
82% to 96%first-pass acceptance
+11%per-encounter reimbursement
60 daysto turn it around
320/moencounters coded
Audited Practice Results
How a 2-location podiatry practice cut its denial rate by two-thirds
THE SITUATION
A 2-location podiatry practice sat at a 19% denial rate, mostly Medicare routine-foot-care and nail-debridement rejections. The denials clustered in three buckets: medical-necessity rejections on routine foot care (missing qualifying diagnosis and class findings), frequency-edit denials on nail debridement billed inside the 60-day window, and missing Q modifiers that flagged services as non-covered.
WHAT QUALIGENIX DID
We built a front-end denial-prevention layer, checking eligibility and coverage against payer LCDs before claims went out, plus a structured appeal workflow with documentation templates mapped to each denial reason.
Key Outcomes & Turnaround
19% to 6%denial rate
$68,000recovered on appealed claims
4 monthsto turn it around
2 locationspractice size
Audited Practice Results
Cancer Surgery Coding by Disease Site
Qualigenix codes cancer surgery by disease site, with the procedure families below.
Breast Cancer Surgery
Partial and total mastectomy codes by extent and node work, image-guided localization device placement by modality and number of lesions, open node biopsy, and the 38900 add-on for intraoperative sentinel node identification.
COMPLIANCE
How We Keep Surgical Oncology Billing Services Billing Compliant
0%
Audit Pass Rate
<0%
Variance Threshold
Why Qualigenix
0%
IMPROPER PAYMENT RATE
0%
FROM DOC GAPS
0%
FROM CODING ERRORS
$0M+
PAID IN ERROR
QUESTIONS BUYERS ASK
Qualigenix charges a percentage of the collections we bring in, so our fee moves with your revenue. The percentage depends on your case volume, payer mix and the services you hand over, and we set it after a call with your team.
Yes. We bill routine services with Q1, investigational items with Q0, report Z00.6 and the eight-digit NCT number, and keep sponsor-paid items off the claim, following Medicare's NCD 310.1.
We review op notes and pathology against codes before release, check teaching-physician and co-surgery documentation, and audit clinical trial claims for correct Q0, Q1 and NCT reporting. Qualigenix holds a 98.6% compliance and audit pass rate.
Yes. We work backlogged cancer surgery claims by payer and denial reason and appeal with the op note and pathology attached. Across all Qualigenix clients, days in A/R have dropped from 54 to 36.
A re-excision after positive margins is usually more extensive than or staged from the original procedure, so it takes modifier 58 and starts a new global. We confirm that against the pathology report and op note, and use 78 instead when the return was for an unplanned complication.
Both surgeons bill the same procedure code with modifier 62, and we coordinate the two claims so neither is denied. Each surgeon's distinct portion of the case has to be documented.
Yes. Qualigenix is system-agnostic and works across 133 EMR/EHR platforms, inside the EHR and practice management system your cancer center already uses.
Qualigenix onboards new practices in 6 days on average. Most surgical oncology groups start with a call to review their trial volume and open global periods.